Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03112603 · OUTCOME

Change From Baseline in EQ-5D-5L

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) · Source last updated 2025-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
scores on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)

What was measured

The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.

Analysis population: FAS. Only participants with available data were analyzed.

Groups in this outcome

Ruxolitinib

Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).

Best Available Therapy

Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ruxolitinib165
Best Available Therapy164

Reported measurements

Cycle 2 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib118
Best Available Therapy98
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.030.214Not reportedNot reportedNot reported
Best Available Therapy-0.010.163Not reportedNot reportedNot reported
Cycle 3 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib113
Best Available Therapy103
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.030.221Not reportedNot reportedNot reported
Best Available Therapy-0.040.259Not reportedNot reportedNot reported
Cycle 4 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib108
Best Available Therapy97
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.040.196Not reportedNot reportedNot reported
Best Available Therapy-0.010.192Not reportedNot reportedNot reported
Cycle 5 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib105
Best Available Therapy88
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.020.210Not reportedNot reportedNot reported
Best Available Therapy-0.030.243Not reportedNot reportedNot reported
Cycle 6 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib96
Best Available Therapy81
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.050.230Not reportedNot reportedNot reported
Best Available Therapy0.010.186Not reportedNot reportedNot reported
Cycle 7 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib89
Best Available Therapy86
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.234Not reportedNot reportedNot reported
Best Available Therapy-0.000.225Not reportedNot reportedNot reported
Cycle 9 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib86
Best Available Therapy42
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.228Not reportedNot reportedNot reported
Best Available Therapy-0.020.166Not reportedNot reportedNot reported
Cycle 12 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib68
Best Available Therapy34
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.187Not reportedNot reportedNot reported
Best Available Therapy0.020.158Not reportedNot reportedNot reported
Cycle 15 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib60
Best Available Therapy30
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.250Not reportedNot reportedNot reported
Best Available Therapy0.030.140Not reportedNot reportedNot reported
Cycle 18 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib56
Best Available Therapy25
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.299Not reportedNot reportedNot reported
Best Available Therapy0.020.110Not reportedNot reportedNot reported
Cycle 21 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib57
Best Available Therapy24
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.080.268Not reportedNot reportedNot reported
Best Available Therapy-0.000.222Not reportedNot reportedNot reported
Cycle 24 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib51
Best Available Therapy22
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.070.272Not reportedNot reportedNot reported
Best Available Therapy0.010.164Not reportedNot reportedNot reported
Cycle 27 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib49
Best Available Therapy21
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.060.299Not reportedNot reportedNot reported
Best Available Therapy0.030.182Not reportedNot reportedNot reported
Cycle 30 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib48
Best Available Therapy19
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.050.261Not reportedNot reportedNot reported
Best Available Therapy0.010.159Not reportedNot reportedNot reported
Cycle 33 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib50
Best Available Therapy19
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.000.282Not reportedNot reportedNot reported
Best Available Therapy0.050.186Not reportedNot reportedNot reported
Cycle 36 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib47
Best Available Therapy18
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.060.231Not reportedNot reportedNot reported
Best Available Therapy0.040.216Not reportedNot reportedNot reported
Cycle 39 Day 1

Analysis denominator · Participants

GroupSource count
Ruxolitinib50
Best Available Therapy18
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ruxolitinib0.060.255Not reportedNot reportedNot reported
Best Available Therapy0.010.214Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.214
        value
        0.03
      2. group Id
        OG001
        spread
        0.163
        value
        -0.01
    denoms
    1. counts
      1. group Id
        OG000
        value
        118
      2. group Id
        OG001
        value
        98
      units
      Participants
    title
    Cycle 2 Day 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.221
        value
        0.03
      2. group Id
        OG001
        spread
        0.259
        value
        -0.04
    denoms
    1. counts
      1. group Id
        OG000
        value
        113
      2. group Id
        OG001
        value
        103
      units
      Participants
    title
    Cycle 3 Day 1
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.196
        value
        0.04
      2. group Id
        OG001
        spread
        0.192
        value
        -0.01
    denoms
    1. counts
      1. group Id
        OG000
        value
        108
      2. group Id
        OG001
        value
        97
      units
      Participants
    title
    Cycle 4 Day 1
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.210
        value
        0.02
      2. group Id
        OG001
        spread
        0.243
        value
        -0.03
    denoms
    1. counts
      1. group Id
        OG000
        value
        105
      2. group Id
        OG001
        value
        88
      units
      Participants
    title
    Cycle 5 Day 1
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.230
        value
        0.05
      2. group Id
        OG001
        spread
        0.186
        value
        0.01
    denoms
    1. counts
      1. group Id
        OG000
        value
        96
      2. group Id
        OG001
        value
        81
      units
      Participants
    title
    Cycle 6 Day 1
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.234
        value
        0.07
      2. group Id
        OG001
        spread
        0.225
        value
        -0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        89
      2. group Id
        OG001
        value
        86
      units
      Participants
    title
    Cycle 7 Day 1
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.228
        value
        0.07
      2. group Id
        OG001
        spread
        0.166
        value
        -0.02
    denoms
    1. counts
      1. group Id
        OG000
        value
        86
      2. group Id
        OG001
        value
        42
      units
      Participants
    title
    Cycle 9 Day 1
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.187
        value
        0.07
      2. group Id
        OG001
        spread
        0.158
        value
        0.02
    denoms
    1. counts
      1. group Id
        OG000
        value
        68
      2. group Id
        OG001
        value
        34
      units
      Participants
    title
    Cycle 12 Day 1
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.250
        value
        0.07
      2. group Id
        OG001
        spread
        0.140
        value
        0.03
    denoms
    1. counts
      1. group Id
        OG000
        value
        60
      2. group Id
        OG001
        value
        30
      units
      Participants
    title
    Cycle 15 Day 1
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.299
        value
        0.07
      2. group Id
        OG001
        spread
        0.110
        value
        0.02
    denoms
    1. counts
      1. group Id
        OG000
        value
        56
      2. group Id
        OG001
        value
        25
      units
      Participants
    title
    Cycle 18 Day 1
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.268
        value
        0.08
      2. group Id
        OG001
        spread
        0.222
        value
        -0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        57
      2. group Id
        OG001
        value
        24
      units
      Participants
    title
    Cycle 21 Day 1
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.272
        value
        0.07
      2. group Id
        OG001
        spread
        0.164
        value
        0.01
    denoms
    1. counts
      1. group Id
        OG000
        value
        51
      2. group Id
        OG001
        value
        22
      units
      Participants
    title
    Cycle 24 Day 1
denoms
  1. counts
    1. group Id
      OG000
      value
      165
    2. group Id
      OG001
      value
      164
    units
    Participants
description
The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.
dispersion Type
Standard Deviation
groups
  1. description
    Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).
    id
    OG000
    title
    Ruxolitinib
  2. description
    Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.
    id
    OG001
    title
    Best Available Therapy
param Type
MEAN
population Description
FAS. Only participants with available data were analyzed.
reporting Status
POSTED
time Frame
Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)
title
Change From Baseline in EQ-5D-5L
type
SECONDARY
unit Of Measure
scores on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice